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Abstract 
Background: Early HIV-1 infection is characterized by high levels of HIV-1 replication and substantial CD4 T cell 
depletion in the intestinal mucosa, intestinal epithelial barrier breakdown, and microbial translocation. HIV-1-induced 
disruption of intestinal homeostasis has also been associated with changes in the intestinal microbiome that are 
linked to mucosal and systemic immune activation. In this study, we investigated the impact of representative bacte-
rial species that were altered in the colonic mucosa of viremic HIV-1 infected individuals (HIV-altered mucosal bacteria; 
HAMB) on intestinal CD4 T cell function, infection by HIV-1, and survival in vitro. Lamina propria (LP) mononuclear cells 
were infected with CCR5-tropic HIV-1BaL or mock infected, exposed to high (3 gram-negative) or low (2 gram-positive) 
abundance HAMB or control gram-negative Escherichia coli and levels of productive HIV-1 infection and CD4 T cell 
depletion assessed. HAMB-associated changes in LP CD4 T cell activation, proliferation and HIV-1 co-receptor expres-
sion were also evaluated.
Results: The majority of HAMB increased HIV-1 infection and depletion of LP CD4 T cells, but gram-negative HAMB 
enhanced CD4 T cell infection to a greater degree than gram-positive HAMB. Most gram-negative HAMB enhanced T 
cell infection to levels similar to that induced by gram-negative E. coli despite lower induction of T cell activation and 
proliferation by HAMB. Both gram-negative HAMB and E. coli significantly increased expression of HIV-1 co-receptor 
CCR5 on LP CD4 T cells. Lipopolysaccharide, a gram-negative bacteria cell wall component, up-regulated CCR5 
expression on LP CD4 T cells whereas gram-positive cell wall lipoteichoic acid did not. Upregulation of CCR5 by gram-
negative HAMB was largely abrogated in CD4 T cell-enriched cultures suggesting an indirect mode of stimulation.
Conclusions: Gram-negative commensal bacteria that are altered in abundance in the colonic mucosa of HIV-1 
infected individuals have the capacity to enhance CCR5-tropic HIV-1 productive infection and depletion of LP CD4 T 
cells in vitro. Enhanced infection appears to be primarily mediated indirectly through increased expression of CCR5 on 
LP CD4 T cells without concomitant large scale T cell activation. This represents a novel mechanism potentially linking 
intestinal dysbiosis to HIV-1 mucosal pathogenesis.
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Background
Human immunodeficiency virus (HIV)-1 disease is asso-
ciated with extensive structural, immunological and 
microbial alterations in the intestinal microenviron-
ment which are thought to contribute to HIV-associated 
chronic immune activation and HIV-1 disease progres-
sion. Early studies utilizing the non-human primate sim-
ian immunodeficiency virus (SIV) animal model of HIV-1 
infection demonstrated that high levels of viral replica-
tion and massive CD4 T cell depletion occurred in the 
intestine as early as 7 days post-infection [1–3]. In HIV 
and SIV infection, extensive depletion of gut T helper 17 
(Th17) and Th22 cells is associated with pathogenesis [4–
8]. In contrast to peripheral CD4 T cells, reconstitution 
of intestinal CD4 T cells following anti-retroviral ther-
apy (ART) is typically delayed and in many individuals, 
reconstitution is incomplete and dependent upon time 
of ART initiation (reviewed in [9]). The immense levels 
of viral replication that occur in the gastro-intestinal (GI) 
tract are likely a consequence of increased permissive-
ness of intestinal CD4 T cells to HIV/SIV infection due to 
high steady state activation status and significant expres-
sion of HIV-1 co-receptors including CCR5 and CXCR4 
and the gut-homing receptor α4β7 [9–20].
Early studies in SIV-infected rhesus macaques sug-
gested that intestinal lamina propria (LP) CD4 T cell 
death occurred both directly via lysis of productively 
infected cells as well as indirectly via apoptotic death of 
bystander cells [3, 21, 22]. To study the mechanisms that 
drive HIV-mediated CD4 T cell death in intestinal tis-
sues, we employed a human intestinal Lamina Propria 
Aggregate Culture (LPAC) model. We demonstrated that 
apoptosis was the primary death pathway in produc-
tively infected CD4 T cells and caspase-1-mediated T cell 
pyroptosis was the primary mechanism for bystander LP 
CD4 T cell death [23]. These observations were in agree-
ment with Doitsh and colleagues who demonstrated in 
ex vivo cultures of tonsil tissues infected with X4-tropic 
HIV-1 that the majority of CD4 T cell death occurred 
in bystander cells as a result of abortive HIV infection, 
accumulation of incomplete HIV reverse transcripts and 
death by pyroptosis [24, 25].
Loss of protective gut Th17 and Th22 cells, along with 
disruption of epithelial barrier integrity (reviewed in 
[26]) leads to the translocation of luminal bacteria and 
bacterial products into the LP and subsequently into the 
systemic circulation [27, 28], termed microbial trans-
location. The process of microbial translocation occurs 
throughout all stages of HIV-1 infection and is consid-
ered to be a major contributor to chronic immune acti-
vation [27–29]. Moreover, despite decreases in levels of 
microbial translocation after initiation of ART, persis-
tence of microbial translocation is associated with poor 
CD4 T cell recovery and non-AIDS morbidity and mor-
tality [29–37]. In the setting of microbial translocation, 
mucosal as well as systemic immune cells are exposed 
to intestinal bacteria and their products. Increased lev-
els of E. coli and lipopolysaccharide (LPS), a gram-neg-
ative bacterial cell wall component, were observed in 
the colonic LP within 28  days post SIV infection [38]. 
In other SIV studies, translocating bacteria enriched for 
Proteobacteria were observed in the mesenteric lymph 
nodes of chronically SIV infected rhesus macaques [39]. 
We reported that levels of both LPS and lipoteichoic 
acid (LTA), a gram-positive cell wall component, were 
increased in the colonic LP of untreated HIV-1-infected 
study participants with a greater fraction of LP myeloid 
dendritic cells (mDCs) and macrophages found in asso-
ciation with LPS than LTA [40].
A number of recent studies have detailed significant 
alterations in the fecal and intestinal mucosal micro-
biomes during treated and untreated HIV-1 infection 
and highlighted a critical role for dysbiosis in driving 
mucosal and systemic immune activation [41–48]. The 
mechanisms by which dysbiosis contributes to inflam-
mation are unclear, but we hypothesize that increased 
translocation of more ‘pathogenic’ bacterial species dur-
ing HIV infection, coupled with a decrease in more ‘pro-
tective’ microbiota, leads to stimulation of mucosal and 
systemic immune cells. We showed that a Prevotella-rich, 
Firmicutes-poor dysbiosis in untreated, HIV-1 infected 
participants was associated with colonic mDC activa-
tion, mucosal and systemic T cell activation, and micro-
bial translocation [41]. Prevotella species that increased 
in abundance in the colonic mucosa during untreated 
HIV-1 infection were associated with colonic mDC acti-
vation levels in vivo and directly activated mDCs in vitro 
[40]. Utilizing the LPAC model, we previously demon-
strated that commensal E. coli activated bacteria-reac-
tive intestinal T cells, augmented HIV-1 replication and 
infection of CD4 T cells [49, 50] and increased the death 
of productively infected cells through increased apopto-
sis in  vitro [23]. However the impact of Prevotella spe-
cies and other altered commensal bacterial species on 
mucosal infection and T cell depletion during HIV-1 
infection remains unclear.
Here, we sought to better understand how differ-
ent bacterial species, in particular those altered in the 
mucosa of HIV-1-infected individuals, may impact CD4 
T cell infection and depletion using the LPAC model. 
Specifically, we studied a panel of representative HIV-
altered mucosal bacteria (HAMB) that increased or 
decreased in relative abundance in the colonic mucosa 
of untreated, viremic HIV-1 infected individuals [40, 41]. 
We show that, although all HAMB increased HIV infec-
tion and depletion of LP CD4 T cells to some degree, 
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gram-negative HAMB appeared to enhance infection and 
depletion to a greater extent than gram-positive HAMB. 
Furthermore, we provide evidence that the increased lev-
els of CD4 T cell infection were likely a consequence of 
bacteria-induced enhancement of CCR5 expression on 
CD4 T cells through indirect mechanisms.
Results
HIV‑altered mucosal bacteria (HAMB) species differentially 
increased productive HIV‑1 infection and LP CD4 T cell 
depletion in vitro
We recently identified 21 mucosa-associated bacte-
rial species that were either increased or decreased in 
relative abundance in HIV-1 infected study participants 
compared to uninfected controls [40] (Additional file 1: 
Table S1). To investigate the potential impact of these 
HAMB [40] species on HIV-1 replication and CD4 T 
cell depletion using the LPAC model, we selected a 
panel of 7 HAMB species that represented each of the 
3 major phyla (Bacteroidetes, Proteobacteria and Firmi-
cutes) and that were identified in the majority of HIV-1 
infected and uninfected study participants (Fig.  1). 
Gram-negative P. copri, P. stercorea (Bacteroidetes) and 
A. junii (Proteobacteria) were all significantly increased 
(Fig.  1b) in the colonic mucosa of HIV-1 infected par-
ticipants and gram-negative B. stercoris and B. thetaio-
taomicron (Bacteroidetes) were decreased (Fig.  1c). 
Gram-positive B. luti and R. bromii (Firmicutes) were 
also decreased in abundance in HIV-1 infected study 
participants (Fig. 1c).
We first evaluated the impact of these HAMB species 
on productive HIV-1 infection levels in LP CD4 T cells 






























































































































































































Fig. 1 Abundances of HIV-altered mucosal bacteria (HAMB) species in HIV-infected and uninfected study participants. Bacterial taxa were identi-
fied in colon biopsies from 17 participants with chronic, untreated HIV-1 infection and 14 uninfected control participants using bacterial 16S 
ribosomal DNA sequencing. Of the 21 species that were significantly over (6) or under (15) represented in HIV-1-infected participants (Additional 
file 1: Table S1), 7 species that represented each of the 3 phyla (Bacteroides, Proteobacteria and Firmicutes) were evaluated in the LPAC model. a 
Phylogenetic tree illustrating taxonomic hierarchy for each HAMB species (GN gram-negative; GP gram-positive). b, c Plots showing individual rela-
tive abundance of each species that were (b) increased or (c) decreased in HIV-1 infected participants (squares) compared to uninfected participants 
(circles). Values are shown as a fraction of all classified species detected within each individual. Lines represent the median value. Statistical analysis 
was performed using the Mann–Whitney test
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in vitro using R5-tropic HIVBaL. Based on extensive data 
on the effect of enteric E. coli (gram-negative) on LP CD4 
T cell infection, activation and depletion [23, 49], E. coli 
was included as a positive control. Lamina propria mon-
onuclear cells (LPMCs) from 11 donors were infected 
with HIVBaL in the presence or absence of E. coli and, at 
4  days post infection (dpi), infection levels were evalu-
ated by intracellular flow cytometry (Fig.  2a) and viable 
CD4 T cells counted. All but 4 donors exhibited >10  % 
CD4 T cell depletion with E. coli. These ‘depleters’ were 
used to compare the ability of different HAMB species 
to enhance LP CD4 T cell infection and depletion. In 
addition, the probiotic Bifidobacterium longum subspe-
cies infantis (B. infantis) was included in these studies. 
Of note, the abundances of E. coli or B. infantis were not 
significantly different in our cohort of untreated HIV-1 
infected study participants compared to uninfected par-
ticipants (p  =  0.63 and p  =  0.53 respectively; data not 
shown).
E. coli significantly enhanced HIV-1 infection in LP 
CD4 T cells as measured by intracellular p24 staining 
as expected [23, 49] (Fig.  2b). Interestingly, all HAMB 
species, irrespective of their abundance in the colonic 
mucosa of HIV-1 infected individuals significantly 
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Fig. 2 HAMB enhance HIV-1 infection and depletion of LP CD4 T cells. LPMC (n = 7) were spinoculated with CCR5-tropic HIV-1BAL or mock control 
and exposed to High abundance or Low abundance HAMB species or to control bacteria (E. coli, B. infantis) (2.5 bacteria: 1 LPMC) for 4 days. LPMC 
were harvested and levels of productive infection and depletion of LP CD4 T cells determined. a Representative gating strategy illustrating intracel-
lular p24 levels in viable CD4 T cells (gated as CD3+ CD8−) in presence or absence of bacteria with gates established on matched mock controls. b 
Percentages of intracellular p24-expressing (p24+) CD4 T cells in presence or absence of bacteria with background p24 (mock) values removed. c 
Levels of CD4 depletion in presence or absence of bacteria relative to depletion in matched mock conditions. Values are shown as ‘box and whisker’ 
with the box extending from the 25th to 75th percentile, the line in the box indicating the median value and the whiskers indicating maximum and 
minimum values. White box indicates no bacteria, light gray boxes indicate HAMB species and dark gray boxes indicate control bacteria. Statistical 
analysis was performed using the Wilcoxon matched–pairs signed rank test comparing frequencies of p24 + CD4 T cells or levels of depletion 
induced in response to bacteria to HIV-1 only. *p < 0.05, #p = 0.08. Legend details the abbreviations used for each bacteria (x axis)
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enhanced HIV-1 infection levels to varying degrees 
except B. luti (p = 0.08) (Fig. 2b). B. infantis significantly 
increased frequencies of p24+  CD4 T cells, although 
to levels generally lower than all other bacteria tested 
(Fig.  2b). Median frequencies of p24+  CD4 T cells 
induced in response to gram-negative bacteria were all 
higher than those induced in response to gram-positive 
bacteria. However, there were differences in the extent 
to which gram-negative bacteria influenced productive 
infection. Of the gram-negative HAMB species tested, P. 
stercorea induced the highest levels of productive infec-
tion, similar in magnitude to E. coli.
Next, we assessed the impact of HAMB on HIV-1 
mediated CD4 T cell depletion (Fig.  2c). Nearly all 
HAMB species increased HIV-1-associated CD4 T cell 
depletion relative to HIV-1 infection without HAMB. P. 
stercorea induced the highest levels of depletion, similar 
to depletion levels induced in response to E. coli, whereas 
enhancement of CD4 T cell depletion by P. copri did not 
reach statistical significance (p = 0.08). Two species that 
induced lower levels of HIV-1 infection, B. luti and B. 
infantis (Fig. 2b), also did not significantly enhance CD4 
T cell depletion (Fig. 2c).
To directly assess if a relationship existed between 
HIV-1 infection and depletion levels, p24+ frequency 
values or depletion values in response to each HAMB 
(n  =  7) from each LPMC donor (n  =  7) were pooled 
(n  =  49 values) and correlation analyses performed. 
Productive HIV-1 infection induced in response to 
HAMB significantly correlated with depletion (r = 0.43, 
p =  0.002; Additional file  2: Figure S1). This result was 
consistent with our previous observation that frequen-
cies of p24+ LP CD4 T cells predicted depletion and that 
depletion was dependent on productive HIV-1 infection 
[23].
HAMB induced low levels of LP CD4 T cell activation 
and proliferation
We previously showed that the increased susceptibility 
of LP CD4 T cells to HIV-1 infection following expo-
sure to E. coli was linked to increased CD4 T cell acti-
vation and proliferation [49]. We therefore evaluated 
bacteria-induced T cell activation, defined as LP CD4 T 
cells co-expressing CD38 and HLA-DR (CD38+ HLA-
DR+) (Fig.  3a). All HAMB except R. bromii increased 
the percentages of CD38+  HLA-DR+  CD4 T cells to 
some degree. P. copri, B. thetaiotaomicron and B. luti 
significantly increased the percentage of CD38+  HLA-
DR+  CD4 T cells compared to unstimulated cul-
tures (Fig. 3b). P. stercorea, A. junii and B. stercoris also 
increased the fraction of CD4 T cells co-expressing CD38 
and HLA-DR but did not reach statistical significance 
(p = 0.06) (Fig. 3b). Notably, the average fold increase in 
CD4 T cell activation induced in response to HAMB (P. 
copri: 5.4×; P. stercorea: 6.4×, A. junii: 5.2×; B. stercoris: 
4.2×, B. thetaiotaomicron: 5.6×, B. luti: 4.0, R. bromii: 
3.6×) were substantially lower than that measured in the 
presence of E. coli (14.4×).
We also evaluated the percentages of CD25-express-
ing CD4 T cells as an additional indicator of T cell acti-
vation (Fig.  3a). Similar to activation assessed as CD38 
and HLA-DR co-expression, HAMB-induced increases 
in CD25 expression varied, but were considerably lower 
(average fold increase: P. copri: 7.0×; P. stercorea: 6.4×, A. 
junii: 6.7×; B. stercoris: 4.3×, B. thetaiotaomicron: 4.6×, 
B. luti: 4.7, R. bromii: 3.5×) than those observed in E. 
coli-exposed cultures (17.1×) (Fig. 3c).
We next assessed levels of CD4 T cell proliferation 
induced in response to bacteria (Fig. 3a). CD4 T cell pro-
liferative responses to HAMB exposure were generally 
much lower than those observed following exposure to E. 
coli (Fig. 3d). Thus, relative to E. coli, the HAMB species 
induced significantly lower levels of CD4 T cell activation 
and proliferation.
HAMB increased CCR5 expression levels on CD4 T cells
To further probe potential mechanisms driving HAMB-
enhanced productive infection of CD4 T cells with a 
CCR5-tropic virus, we next evaluated the expression of 
the HIV-1 co-receptors CCR5 and CD4 on LP CD4 T cells 
following bacterial exposure (Fig.  4a). CCR5 expression 
levels were significantly increased following exposure to 
all gram-negative HAMB but not for gram-positive B. luti 
and R. bromii (Fig.  4b). On average, the fold increase in 
CCR5 expression on CD4 T cells in response to exposure 
to each gram-negative HAMB (P. copri: 1.7×; P. stercorea: 
2.0×, A. junii: 1.9×; B. stercoris: 1.7×, B. thetaiotaomi-
cron: 2.0×) was comparable to that induced by E. coli 
(2.3×). Only P. copri, B. stercorea, B. luti and R. bromii sig-
nificantly increased CD4 expression levels on CD4 T cells 
and to levels generally lower than those measured on CD4 
T cells in response to exposure to E. coli (Fig. 4c).
Bacteria‑induced increases in CCR5 expression may be 
mediated in part by the cell wall component LPS
To dissect potential mechanisms behind the upregulation 
of CCR5 expression in response to exposure to whole 
bacteria, we investigated CCR5 expression levels on CD4 
T cells in response to exposure of LPMC to individual 
bacterial products highly expressed in the surface mem-
brane of gram-negative (LPS) and gram-positive (LTA) 
bacteria. LPS significantly increased CCR5 expression 
whereas exposure to  LTA did not (Fig.  5a). This lack of 
CCR5 induction was not related to LTA concentration as 
increasing doses of LTA (up to 50 μg/ml) failed to signifi-
cantly induce CCR5 expression (data not shown).
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To determine whether CCR5 upregulation by gram-
negative bacteria occurred early in culture and thereby 
lead to enhanced HIV-1 infection of CD4 T cells, LPMC 
from 7 donors were exposed to P. stercorea or LPS and 
CCR5 expression levels evaluated after 24  h. At 24  h, 
significant increases in CCR5 expression on CD4 T cells 
were observed in response to both P. stercorea (median 
mean fluorescence intensity (MFI): 1723, range 592–
3577; p =  0.016) and LPS (1407, 577–3062; p =  0.016) 
above no stimulation (1183, 463–2365).
Bacteria‑associated increases in CCR5 expression 
on LP CD4 T cells occurs indirectly and is not mediated 
through TCR signaling
We previously showed that commensal E.coli-associated 
enhancement of productive HIV-1 infection of LP CD4 T 
cells was dependent on the presence of LP mDC and was, 
in part, mediated through an MHC-Class II dependent 
mechanism [49]. Therefore, we next determined whether 
upregulation of CCR5 on T cells by P. stercorea and LPS 
was mediated directly via bacteria/T cell interaction or 
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Fig. 3 HAMB induce low levels of LP CD4 T cell activation and proliferation. LPMC (n = 6) were pre-labeled with CFSE and exposed to High abun-
dance or Low abundance HAMB species or to control bacteria (E. coli, B. infantis) (2.5 bacteria: 1 LPMC) for 5 days. LPMC were harvested and frequen-
cies of activated (CD38+HLA-DR+, CD25+) and proliferating (CFSElo) LP CD4 T cells were evaluated using flow cytometry. a Representative gating 
strategy illustrating CD38+HLA-DR+, CD25+ and CFSE profiles of viable LP CD4 T cells in presence or absence of bacteria with gates established on 
media (CD25+, CFSE) or FMO controls (CD38/HLA-DR). b Percentages of LP CD4 T cells co-expressing CD38 and HLA-DR. FMO control values have 
been subtracted. c Percentages of CD4 LP T cells expressing CD25. d Percentages of CFSElo LP CD4 T cells. Values are shown as symbols representing 
each individual donor to highlight the 1 donor that exhibited unusually high responses to HAMB. Line indicates the median value. Statistical analysis 
was performed using the Wilcoxon matched–pairs signed rank test comparing percentages of activated or proliferating LP CD4 T cells induced in 
response to bacteria to no bacteria. *p < 0.05, #p = 0.06. Legend details the abbreviations used for each bacteria (x axis)
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indirectly (potentially through bacteria/antigen present-
ing cell (APC) interactions). LP cells highly enriched for 
CD4 T cells (>92  % of viable CD45+ cells) were stimu-
lated in the presence or absence of P. stercorea or LPS and 
levels of CCR5 expression on CD4 T cells compared to 
CCR5 expression levels on CD4 T cells induced in total 
LPMC cultures (Fig. 5b). In the presence of P. stercorea, 
levels of CCR5 expression on CD4 T cells were, on aver-
age, 78 % (±10.5 % SEM) lower in CD4 T cell-enriched 
cultures compared to CD4 T cells levels measured when 
total LPMC were exposed to P. stercorea. Exposure of 
CD4 T cell-enriched cultures to LPS completely failed to 
induce CCR5 expression (Fig. 5b).
To determine if direct TCR stimulation increased 
CCR5 expression on LP CD4 T cells, we exposed LPMC 
to beads that signal through CD3, CD2 and CD28. As 
expected, direct TCR-mediated signaling significantly 
increased expression of CD4 T cell activation markers 
CD38 and HLA-DR (Fig. 5c). However, levels of CCR5 on 
CD4 T cells were not increased after 5 days of stimula-
tion of LPMC with CD3/CD2/CD28 beads compared to 
levels observed in unstimulated cultures (Fig. 5c).
Discussion
HIV-1 infection is associated with major structural and 
immunological disruption of the GI tract due in part to 
high levels of HIV-1 replication and CD4 T cell depletion 
that occur in the earliest stages of infection. In recent 
years, a number of research groups including ours [40–
48], have linked alterations in the intestinal microbiome, 
termed dysbiosis, in HIV-1 infected individuals to intes-
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Fig. 4 HAMB increase CCR5 expression on LP CD4 T cells. LPMC (n = 6) were exposed to High abundance or Low abundance HAMB species or 
to control bacteria (E. coli, B. infantis) (2.5 bacteria: 1 LPMC) for 5 days. LPMC were harvested and expression levels of HIV-1 co-receptors CCR5 and 
CD4 on LP CD4 T cells determined using flow cytometry. a Representative gating strategy illustrating CCR5 and CD4 expression on viable LP CD4 
T cells in presence or absence of bacteria. b Expression levels (Mean fluorescence intensity; MFI) of CCR5 on CD4 LP T cells. Isotype control values 
have been subtracted (net MFI). c CD4 expression levels (MFI) on LP CD4 T cells. Values are shown as ‘box and whisker’ with the box extending from 
the 25th to 75th percentile, the line in the box indicating the median value and the whiskers indicating maximum and minimum values. White box 
indicates no bacteria, light gray boxes indicate HAMB species and dark gray boxes indicate control bacteria. Statistical analysis was performed using 
the Wilcoxon matched–pairs signed rank test comparing CCR5 or CD4 expression levels on LP CD4 T cells induced in response to bacteria to no 
bacteria. *p < 0.05, #p = 0.06. Legend details the abbreviations used for each bacteria (x axis)
Page 8 of 14Dillon et al. Retrovirology  (2016) 13:5 
demonstrated that E. coli, an enteric bacterial species, 
augmented HIV-replication in LP CD4 T cells and drove 
apoptotic T cell death in  vitro [23, 49]. However, our 
recent analyses revealed that E. coli abundance was not 
significantly different in colonic mucosa of untreated, 
viremic HIV-1 infected individuals compared to unin-
fected study participants. Instead, other bacterial spe-
cies, particularly Prevotella species, were altered [40, 41]. 
Increased abundances of Prevotella in fecal and colonic 
tissue samples from untreated and treated HIV-1 infected 
individuals have also been reported by others [44, 45, 47, 
51]. However, only one other group identified these down 
to the species level and in fecal rather than mucosal sam-
ples [44]. The study by Lozupone and colleagues showed 
HIV-associated increased fecal abundances of P. copri 
and P. stercorea and decreased abundances of B. thetaio-
taomicron and A. putredinis, [44] similar to our observa-
tions in the colonic mucosa of untreated HIV-1-infected 
individuals. This current study was undertaken to further 
understand the potential mechanisms by which altered 
intestinal microbiota adherent to the colonic mucosa 
(HAMB), and therefore more likely to interact with intes-
tinal immune cells, may contribute to HIV-1-associated 
mucosal pathogenesis. We utilized the LPAC model [23] 
to investigate the impact of HAMB species on LP CD4 
T cell infection and depletion in  vitro. We further used 
this ex vivo model system to probe potential microbiota-
associated mechanisms that drive these responses.
Exposure of LP CD4 T cells to a panel of HAMB 
resulted in enhanced productive CCR5-tropic HIV-1 
infection, similar to our previous results with E.coli [23, 
49]. In particular, commensal E. coli strongly enhanced 
HIV-1 replication in LPMCs and this was linked to high 
levels of LP CD4 T cell activation and proliferation [49]. 
Surprisingly, the levels of CD4 T cell activation and pro-
liferation induced in response to HAMB were substan-
tially lower than those observed in response to E. coli. 
This apparent disconnect between HAMB-associated 
increased T cell activation and productive HIV-1 infec-
tion was most apparent for P. stercorea, which enhanced 
productive HIV-1infection to similar levels as induced 
by E. coli. These observations suggest that mecha-
nisms other than increased T cell activation underlie 
the observed HAMB-mediated enhancement of HIV-1 
infection.
High expression levels of CCR5, an HIV co-receptor, 
on LP CD4 T cells has also been implicated in their natu-
ral permissivity and susceptibility to HIV infection [10, 
16, 18, 19, 52]. We theorized that modulation of CCR5 
expression might be one mechanism responsible for bac-
teria-induced increased T cell infectivity with R5-tropic 
virus. Consistent with this theory, CCR5 was significantly 


























































































































Fig. 5 HAMB-mediated increased CCR5 expression is a result of 
indirect stimulation of LP CD4 T cells. a CCR5 expression in response 
to individual TLR ligands (TLRL) was measured by exposing LPMC 
(n = 6–7) to TLR4L (commensal E. coli LPS, 1 μg/ml) or TLR2L (Bacillus 
subtilis LTA, 1 μg/ml) or cultured without TLRLs (None) for 5 days. 
LPMC were harvested and CCR5 expression levels (Mean fluorescence 
intensity; MFI) on LP CD4 T cells evaluated. Isotype control values 
have been subtracted (net MFI) and values are illustrated as ‘box and 
whisker’ with the box extending from the 25th to 75th percentile, 
the line in the box indicating the median value and the whiskers 
indicating maximum and minimum values. Statistical analysis was 
performed using the Wilcoxon matched–pairs signed rank test, 
*p < 0.05. b Levels of CCR5 expression on LP CD4 T cells in response 
to stimulation of total LPMC or CD4-enriched LP cells with P. stercorea 
(2.5:1 LPMC/CD4 T cell) or E. coli LPS (1 μg/ml) for 24 h. Values shown 
are mean ± SEM of stimuli–specific CCR5 expression levels (net; no 
stimulation values subtracted; n = 3). Percent values indicate the 
average decrease in levels of CCR5 expression on CD4 T cells stimu-
lated directly relative to expression levels on CD4 T cells from total 
LPMC stimulated cultures. Statistical analysis was performed using 
Paired t test, *p < 0.05, #p = 0.07. (C) LPMC (n = 6–7) were exposed 
to CD3/CD2/CD28 beads (1 bead: 2 LPMC) or cultured without 
exogenous stimuli (None) for 5 days. LPMC were harvested and 
frequencies of activated (CD38+HLA-DR+; CD25+) LP CD4 T cells and 
CCR5 expression levels determined. Values are shown with isotype 
(CCR5) or FMO control values removed and illustrated as ‘box and 
whisker’ plots. Statistical analysis was performed using the Wilcoxon 
matched–pairs signed rank test. *p < 0.05
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HAMB. In fact, the levels of CCR5 induced in response 
to certain gram-negative HAMB (i.e. P. stercorea) were 
approaching the high levels induced in response to E. 
coli. Notably, increased CCR5 expression on blood and 
lung CD4 T cells in patients with tuberculosis with or 
without HIV-1 infection was proposed as a mechanism 
for the increased HIV viremia and hastened course of 
HIV progression associated with tuberculosis co-infec-
tion [53–55]. Exposure of whole blood to mycobacterial 
lipoarabinomannan in  vitro increased CCR5 expression 
on blood CD4 T cells, suggesting the increased levels 
of CCR5 expression in tuberculosis patients was medi-
ated, at least in part, by cell wall components of Myco-
bacterium tuberculosis [53]. Moreover, the oral pathogen 
Porphyromonas gingivalis increased CCR5 expression 
on oral keratinocytes in  vitro, and may play a role in 
the selection of R5-tropic HIV-1 in the oral mucosa [56, 
57]. We now provide the first evidence that commen-
sal enteric bacteria are capable of augmenting CCR5 
expression on intestinal LP CD4 T cells. We hypoth-
esize that, in the context of dysbiosis and microbial 
translocation, this process further enhances productive 
infection by R5-tropic HIV-1 and contributes to the dis-
ruption of intestinal T cell homeostasis in HIV-1 infected 
individuals.
Regardless of taxonomic grouping and the relative lev-
els of abundance in vivo, HAMB species enhanced HIV-1 
infection in LP CD4 T cells. However, gram-negative bac-
teria increased productive infection to a greater degree 
than gram-positive bacteria. Potentially explaining this 
observation, exposure of LPMCs to the gram-negative 
bacterial cell wall component LPS enhanced CCR5 
expression whereas exposure to LTA, a constituent of 
cell walls of gram-positive bacteria did not. This suggests 
that LPS may in part explain why gram-negative bacte-
ria were particularly efficient at enhancing HIV-1 infec-
tion of LP CD4 T cells. Interestingly, all high abundance 
HAMB species were gram negative. Thus, in the context 
of microbial translocation, there would be a greater ten-
dency for LP immune cells to be exposed to these gram-
negative bacteria and their components. This implies a 
greater contribution of high abundance, gram-negative 
HAMB to HIV-associated LP immune dysfunction.
LPMCs are composed not only of effector memory 
CD4 T cells, but also of additional immune cells such as 
mDCs that direct immunogenic and tolerogenic intes-
tinal immune responses [58] and play a role in viral dis-
semination [59]. In this study, the effects of both whole 
bacteria (P. stercorea) and LPS on CCR5 upregulation did 
not appear to result from direct stimulation of LP CD4 T 
cells. We previously showed a requirement for LP mDC 
in the activation and expansion of bacteria-reactive T 
cells as well as in the bacteria-associated enhancement 
of LP CD4 T cell infection mediated, in part, through 
MHC Class II-restricted antigen presentation [49, 50]. 
Our observations that direct T cell receptor activation in 
conjunction with CD28 co-stimulation of LP CD4 T cells 
did not result in CCR5 upregulation suggests that TCR-
mediated activation by mDCs presenting bacterial anti-
gens is unlikely to be solely sufficient to increase CCR5. 
Thus, our results suggest that bacterial antigens may 
prompt DCs, or other immune cells, to produce immune 
factors that then promote CCR5 upregulation on LP CD4 
T cells. The mediators and signaling pathways involved 
in bacteria-associated CCR5 upregulation on LP CD4 T 
cells remain to be determined.
Although these studies begin to probe potential mech-
anisms by which an altered microbiome may drive HIV-
associated mucosal pathogenesis, a limitation to the 
in vitro model is that it does not reflect the complexity of 
the microbiome in vivo, either in context of reflecting the 
microbial community as a whole or the collective impact 
that metabolites and other factors produced by bacte-
ria may have on intestinal T cell infection and depletion 
in vivo.
Conclusions
The present study provides the first evidence that com-
mensal bacteria that are altered in the colonic mucosa 
of untreated, viremic HIV-1 infected individuals 
enhance both productive infection and depletion of LP 
CD4 T cells by CCR5-tropic HIV-1 ex  vivo. Although 
all HAMB increased HIV-1 infection and depletion of 
LP CD4 T cells to some degree, gram-negative HAMB 
appeared to enhance infection and depletion greater 
than gram-positive HAMB. Somewhat unexpectedly, 
high abundance HAMB that induced significantly high 
levels of productive infection and CD4 T cell death 
similar to E. coli facilitated only minimal increased LP 
T cell activation. However, these same bacteria induced 
substantial increases in CCR5 expression on LP CD4 
T cells. These observations highlight that bacteria may 
utilize different mechanisms to contribute to HIV-
associated pathogenesis. Increases in CCR5 expression 
by HAMB were mediated by indirect stimulation of LP 
CD4 T cells and likely mediated in part through LPS 
signaling. Recognizing how dysbiosis impacts HIV-1 
infection and death of intestinal CD4 T cells and deter-
mining the potential mechanisms that drive these bac-
teria-associated T cell responses will provide a better 
understanding of HIV-1-associated mucosal pathogen-
esis and lead to novel treatment approaches that target 
the microbiome and/or its downstream effects on the 
intestinal immune system.
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Methods
Determination of colonic mucosa‑associated bacterial 
species
Seventeen HIV-1 infected individuals and 14 HIV-1 
seronegative (uninfected) controls who met the entry 
criteria were enrolled in this cross-sectional study at 
the University of Colorado Anschutz Medical Campus. 
Study design including study entry and exclusion crite-
ria are extensively detailed in previous publications [40, 
41]. Efforts were made to enroll HIV-1 seronegative study 
participants who were matched for age and sex to the 
HIV-1 infected participants. HIV-1 infected participants 
were ART-treatment naïve or had not been on treatment 
for more than 7 days in the preceding 6 months. The clin-
ical details for study participants are provided in Addi-
tional file  3: Table S2. All study participants voluntarily 
gave written, informed consent. This study was approved 
by the Colorado Multiple Institutional Review Board 
(COMIRB) at the Anschutz Medical Campus.
Laboratory and analytic methods used to profile 
the intestinal microbiomes of study participants were 
described previously [40, 41]. Briefly, species-level taxo-
nomic classification of 16S rRNA sequence datasets was 
obtained via BLAST [60] of subject sequences against a 
database built from Silva [61] bacterial sequences marked 
as type strains, cultivars, or genomes. A species name 
was assigned when a sequence overlapped the Silva data-
base sequence by at least 95  % sequence length with at 
least 99  % sequence identity and the taxonomy of the 
database hit matched the taxonomy returned by SINA 
[62] as determined previously [41]. Most sequences were 
classified assignable to a species (median 97.4  %, inter-
quartile range 94.6–98.6 %).
Human intestinal Lamina Propria Aggregate Culture (LPAC) 
model
Human jejunum tissue samples (n =  16) were obtained 
from patients undergoing elective abdominal surgery, 
represent otherwise discarded tissue and were consid-
ered macroscopically normal as previously described 
[23, 40, 49, 50, 63]. Those with a history of inflamma-
tory bowel disease, recent chemotherapy or radiation or 
immunosuppressive drugs were excluded from the study. 
All patients undergoing surgery signed a release to allow 
the unrestricted use of discarded tissues for research pur-
poses, and all protected patient information was de-iden-
tified to the laboratory investigators. This research was 
reviewed by the Colorado Multiple Institutional Review 
Board (COMIRB) at the University of Colorado Ans-
chutz Medical Campus and was granted exempt research 
status. LPMC were isolated from tissue samples and 
released LPMC were cryopreserved and stored in liquid 
nitrogen as detailed elsewhere [23, 40, 49, 50, 63].
Preparation of commensal bacterial stocks
Expansion of P. copri (DSM No. 18205, DSMZ, Braun-
schweig, Germany), P. stercorea (DSM No. 18206), B. 
stercoris (ATCC 43183, ATCC Manassas, VA, USA), 
B. thetaiotaomicron (ATCC 29741), B. luti (DSM No. 
14534), R. bromii (ATCC# 27255) and Bifidobacterium 
longum subsp infantis (ATCC 15697) was performed at 
37  °C under anaerobic conditions achieved by using a 
BD GasPak EZ Anaerobe Pouch System (BD Diagnos-
tics, Franklin Lakes, NJ, USA) per manufacturer’s pro-
tocols with slight modifications. Specifically, P. copri 
was expanded by culturing on Brucella plates (BD Diag-
nostics) for 5–7  days; P. stercorea was expanded in liq-
uid chopped meat broth (Hardy Diagnostics, Santa 
Maria, CA, USA) supplemented with 1  % Trace Miner-
als (ATCC), 1  % Vitamin Supplements (ATCC), 0.05  % 
Tween80, 29.7  mM acetic acid, 8.1  mM propionic acid 
and 4.4 mM butyric acid (all Sigma-Aldrich) for 5–7 days; 
B. stercoris, B. thetaiotaomicron, B. luti, R. bromii and 
Bifidobacterium longum subsp infantis were expanded 
in liquid chopped meat broth (BD Biosciences; Hardy 
Diagnostics) for 1–2  days with the exception of Bifido-
bacterium longum subsp infantis which was expanded for 
2–3 days. Expansion of A. junii (ATCC 17908) and E. coli 
(ATCC 25922) was performed under aerobic conditions 
at 26 and 37 °C respectively. A. junii was expanded using 
Nutrient Agar plates (Edge Biologicals, Memphis, TN, 
USA) and E. coli expanded in LB broth (Sigma-Aldrich) 
for 1–2  days. All bacteria were stored long-term at 
−80 °C in 10 % glycerol. To prepare working stocks, bac-
teria were expanded from long-term stocks as described 
above except for B. stercoris, B. thetaiotaomicron and 
Bifidobacterium longum subsp infantis which were grown 
on Brucella plates and E. coli which was grown on LB 
Agar plates (Teknova, Hollister, CA, USA). Bacteria were 
suspended in DPBS and stored at −80  °C in single-use 
aliquots. Bacterial enumeration was performed as previ-
ously detailed [40].
Preparation of CCR5‑tropic HIV‑1Ba‑L stocks
Preparation of HIV-1 viral stocks was performed as pre-
viously detailed [23]. Briefly, MOLT4-CCR5 cells (AIDS 
Research and Reference Reagent Program; ARRP Cata-
log# 510) were infected with R5-tropic HIV-1Ba-L strain 
(ARRP #4984) or mock-infected in the presence of poly-
brene (Santa Cruz Biotechnology, Dallas, TX, USA). 
Additional MOLT4-CCR5 cells were provided 4  days 
post infection (dpi) and culture supernatants collected 
9dpi. Concentrated viral stocks were obtained by ultra-
centrifugation at 141,000×g for 2  h. Concentrations of 
p24 in the supernatant was determined by HIV Gag p24 
ELISA (Perkin Elmer, Walthman, MA, USA). Virus and 
mock stocks were frozen in single use aliquots at −80 °C.
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LPMC infection assay
The LPMC infection assay that has been previously 
detailed [23] was used with slight modifications to 
account for a 96-well plate format. LPMCs were thawed 
using a standard protocol as detailed [23] and resus-
pended in RPMI  +  10  % human AB serum (Gemini 
Bioproducts, West Sacramento, CA, USA) +  1  % peni-
cillin/streptomycin/glutamin (Life Technologies, Grand 
Island, NY, USA) (cRPMI) +  500 µg/ml Zosyn (pipera-
cillin/tazobactium; Wyeth, Madison, NY, USA) (cRPMI). 
HIV-1Ba-L (10 ng p24 per 1 ×  106 LPMCs) was used to 
infect primary LPMCs at 2.5 × 106 LPMCs/ml. LPMCs 
were mock infected in parallel. Infection by spinocula-
tion was performed at 1500×g for 2  h at room tem-
perature. After 2  h supernatant containing the free 
virus was discarded and the LPMCs were washed with 
cRPMI. LPMCs were resuspended at 1  ×  106 LPMCs/
ml in cRPMI and plated into triplicate wells of a 96-well 
V-bottom culture dish and live bacteria added where 
appropriate. LPMCs were cultured for 4  days at 37  °C, 
5 % CO2 and 95 % humidity.
LPMC stimulation with commensal bacteria, TLR ligands 
and T cell activation beads
Whole bacteria was added to cell cultures at 2.5 bacte-
ria: 1 LPMC as previously described [40]. Commensal E. 
coli LPS (InvivoGen, San Diego, CA, USA) and B. subtilis 
LTA (InvivoGen) were added at 1 μg/ml. For TLR ligand 
dose titration assays, LPS and LTA were also added at 5 
and 50 μg/ml. T cell receptor (TCR)-mediated T cell acti-
vation was performed using CD3/CD2/CD28 beads (T 
cell Activation/Expansion Kit, Miltenyi Biotec, Auburn, 
CA, USA) at a ratio of 1 bead to 2 LPMC.
Measurement of T cell proliferation, activation and CCR5 
expression
To measure levels of T cell proliferation and activation 
in response to the panel of 7 HAMB, LPMC were pre-
labelled with 1  μM CellTrace CFSE (Invitrogen, Grand 
Island, NY, USA) per manufacturer’s instructions. CFSE-
labeled cells were mock-infected by spinoculation and 
plated in triplicate in 96-well plates as detailed above. 
LPMCs were cultured with or without bacteria for 5 days 
at 37 °C, 5 % CO2 and 95 % humidity. Total LPMCs were 
collected and CD4 T cell proliferation, levels of T cell 
activation and expression levels of CCR5 were deter-
mined by multi-color flow cytometry.
To determine T cell activation and CCR5 expression 
levels in response to TLR ligands, TCR-mediated sign-
aling and P. stercorea, LPMC were cultured in cRPMI in 
a 48well plate for 24 h or 5 days at 37  °C, 5 % CO2 and 
95 % humidity in the presence or absence of E. coli LPS, 
B. subtilis LTA, CD3/CD2/CD28 beads or bacteria and 
levels of T cell activation and expression levels of CCR5 
determined by multi-color flow cytometry.
Enrichment of LP CD4 T cells
LPMC were highly enriched for CD4 T cells using col-
umn-based immunomagnetic selection and the EasySep 
magnet (Stemcell Technologies, Vancouver, BA, Canada). 
Firstly, LPMC were stained with biotinylated CD11c 
(eBioscience, San Diego, CA, USA) and control LPMC 
(total LPMC) resuspended in buffer only. FcR blocking 
reagent (Miltenyi Biotec) was added to all conditions. 
Biotinylated CD11c-bound cells were removed using the 
EasySep Biotin Selection Kit (Stemcell Technologies) 
following the manufacturers protocol. Next, CD11c-
depleted LPMC were enriched for CD4 LP T cells using 
the EasySep Human CD4+  T cell isolation kit (Stem-
cell Technologies) per manufacturers’ protocol. Control 
LPMC were incubated with buffer in place of the CD4+ 
T cell Enrichment Cocktail. All other steps in the proto-
col were the same as those followed to enrich for LP CD4 
T cells. Multi-color flow cytometry was used to evaluate 
CD4 T cell frequencies as well as frequencies of non-CD4 
T cells (CD8 T cells, γδ T cells, B cells, mDC) in both 
CD4-enriched LPMC and in total LPMC. On average, 
CD4 T cells were enriched to 92.9 % (of viable, CD45+ 
cells; n =  3). CD4-enriched LPMC or total LPMC were 
cultured for 24 h at 37 °C, 5 % CO2 and 95 % humidity in 
the presence or absence of P. stercorea or E. coli LPS and 
levels of expression of CCR5 on CD4 T cells determined 
by multi-color flow cytometry.
Surface and intracellular flow cytometry staining assays
All antibodies and dyes are listed in Additional file  4: 
Table S3. Standard flow cytometry staining protocols to 
determine expression of surface markers (LP cell iden-
tification, proliferation, activation, HIV-1 co-receptor 
expression) and intracellular expression of HIV-1 core 
antigen (p24) were followed as previously detailed [23, 
49].
Flow cytometry acquisition and analysis
To measure productive infection (p24), flow cytom-
etry data was acquired on a Gallios 561 flow cytometer 
(Beckman Coulter) using the Hypercyte 96-well plate 
reader and analyzed using Kaluza software version 1.2 
(Beckman Coulter). All other flow cytometry data was 
acquired on an LSRII flow cytometer (BD Biosciences) 
and analyzed using BD FACS DIVA version 6.1.3 as pre-
viously detailed [49].
To identify LP CD4 T cells, a total lympho-
cyte gate based on forward and side scatter 
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properties was determined in viable (aqua dye−) cells 
and doublets excluded based on forward-scatter-height 
versus forward-scatter-width properties. HIV-1 down-
regulates CD4 expression [64], therefore frequencies of 
p24-expressing LP CD4 T cells were determined by gat-
ing CD4 T cells as CD3+ CD8− T cells as previously 
detailed [23, 49]. For all other assays, CD4 T cells were 
identified as CD3+ CD4+ CD8− T cells. Proliferat-
ing CD4 T cells were enumerated as the percentage of 
CFSElo CD4 T cells with the CFSE gate established on the 
unstimulated condition. T cell activation was determined 
by evaluating the percentage of CD4 T cells that co-
expressed CD38 and HLA-DR as well as the percentage 
of cells that expressed CD25. Expression of CCR5 was 
evaluated as the mean fluorescence intensity (MFI) on 
CD4 T cells. Expression levels of CD4 on CD4+ T cells 
were also assessed as MFI. In all cases except expression 
levels of CD4 on CD4 T cells, isotype or FMO control 
values were subtracted and data displayed as ‘net’ values.
To quantify depletion, the difference in the num-
ber of viable T cells in HIV-1-infected cultures com-
pared to the number of viable T cells in matched 
mock-infected cultures was reported as the per-
centage of viable T cells in mock-infected control 
wells [23]. For example, if 100,000 viable T cells 
were measured in an HIV-infected well and 500,000 
viable T cells measured in mock-infected cultures, 
the percent depletion would be reported as 80  %. 
The number of absolute viable T cells in each con-
dition was calculated as previously detailed with 
some modifications [23]. Specifically, LPMC were 
collected at the completion of the culture period 
and counted using a TC20 Automated Cell Coun-
ter (Bio-Rad Laboratories, Hercules, CA, USA) 
with viable cells calculated based on Trypan Blue 
(Hyclone Laboratories, Logan, UT, USA) exclusion. 
The viable cell count was then multiplied by the per-
centage of viable CD3+ CD8− T cells measured by 
flow cytometry to determine the absolute number of 
viable cells in each well. All conditions were run in 
triplicate wells with the average depletion for the 3 
wells reported.
Statistical analysis
Statistical analysis and graphing were performed using 
GraphPad Prism version 6 for Windows (GraphPad Soft-
ware, San Diego, CA, USA). Non-parametric tests were 
performed to determine differences between groups of 
matched paired data using Wilcoxon’s matched-pairs 
signed-rank test and Spearman test to determine correla-
tions between variables. A paired t test was used to eval-
uated differences between groups in the CD4− enriched 
LPMC assays due to small sample size (n = 3).
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